🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our very own Dr. Padmanee Sharma for alice + olivia! We are so grateful for her contribution to Abraham’s tent - the Sharmallison scholarship! If you are interested in learning more, please visit our website - link in our bio! For full video: instagram.com/tv/CUOFImugb9c…

Many thanks for highlighting our work !! Cancer Discovery Elizabeth McKenna

Our recent collaboration work is out at Materials Today Bio. "Bone mineral: A trojan horse for bone cancers efficient mitochondria targeted delivery and tumor eradication with nano hydroxyapatite containing doxorubicin" sciencedirect.com/science/articl… #Cancer #CancerResearch #CellBiology

Excited to highlight our research in Nature Medicine, which demonstrates that #antibiotic exposure and the gut #microbiome are linked to #CARTcell efficacy & toxicity. Stanford Department of Medicine Stanford BMT & Cell Therapy Memorial Sloan Kettering Cancer Center Penn Medicine Marcel van den Brink Marco Ruella #AndreaFacciabene

In Nature Reviews Immunology, Stanley Perlman argues "a 'normal' immune response often results in a transient disequilibrium of tissue homeostasis, and this is required for clearance of an infection but can contribute to disease," in respect to SARS1 ncbi.nlm.nih.gov/labs/pmc/artic…

Importance of ctDNA. In neoadjuvant study, no benefit from PDL1i in ctDNA- but in + there was benefit. Also, Pts who were positive but cleared did as well as negative.

Latest work in Nature Immunology. Using a systematic computational and biological approach we identify IFN-I as a major driver of coinhibitory receptor regulation in human T cells. Fantastic collaboration with Asaf Madi, Hafler Lab Yale School of Medicine Tomokazu Sumida! rdcu.be/cJctS

So excited to see FDA approval of the first anti-LAG3, in combination with anti-PD1! It has been a long road but we have had the pleasure of working with an amazing team of trainees and collaborators dissecting LAG3 function since ~2020 (20+ papers)! 1/2 news.bms.com/news/details/2…

A key paper was the first demonstration in mouse cancer models of synergistic activity with the combination of anti-PD1 & anti-LAG3, in collaboration with our colleagues at Hopkins (Chuck Drake/Drew Pardoll) & BMS (Alan Korman/Mark Selby), plus others! 2/2 pubmed.ncbi.nlm.nih.gov/22186141/

Behold, the U2OS “cancer dance” This one was hungry 😅 w/ Nathan Shaner 🏳️‍🌈

Excited to share our review on natural killer cells in cancer metastasis! UTSW Simmons Cancer Center

Louis Kahn designed the Salk Institute so that twice a year, on the spring and fall equinoxes, the setting sun lines up with the "River of Life" in the Salk courtyard. Happy Spring! #HappySpring salk.edu/about/building…

Rare cancers collectively make up 25 percent of cancer mortality in the U.S. Karlyne Reilly, PhD, began to study rare tumors with the help of a grant from the AACR. Read more: bit.ly/3D1SD3e #AACRGrants @NCIResearchCtr

If you are a scientist and are willing to engage in climate civil disobedience that could potentially include risk of arrest, please contact me.

Dr Ann Partridge MD, MPH discussed Treatment of #BreastCancer in Young Adults at #ASCO22, touching on topics like local age-specific diagnosis; prognostics and disparities; role of chemo; local therapy; adherence; fertility & pregnancy; body image, sexual health and psychosocial needs

Why are certain mutations so prevalent in some but not other cancers? A clue: They need to cooperate with lineage-specific transcription factors to activate an oncogenic programme. Really beautiful paper out in nature by Sakari Vanharanta and his team. Btw, he's hiring University of Helsinki!

Delighted to be with Jennifer Guerriero, PhD Society for Immunotherapy of Cancer Bernard A Fox and others to discuss #immunotherapy!